Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. - Wikidata - awgldk - TriplyDB

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

http://www.wikidata.org/entity/Q33475538

about

Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study Opportunities and challenges for successful use of bevacizumab in pediatrics.Functional imaging in adult and paediatric brain tumours.Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients Antiangiogenic therapy of brain tumors: the role of bevacizumab.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Advanced MR Imaging in Neuro-oncology.Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.Genetics of glioblastoma: a window into its imaging and histopathologic variability.Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma.Advances in MRI assessment of gliomas and response to anti-VEGF therapy.Diffusion tensor histogram analysis of pediatric diffuse intrinsic pontine glioma Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab.Quantitative evaluation of multi-parametric MR imaging marker changes post-laser interstitial ablation therapy (LITT) for epilepsy.Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.Antiangiogenic therapy for glioblastoma.Neuroimaging findings of the post-treatment effects of radiation and chemotherapy of malignant primary glial neoplasms Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models.Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches Antiangiogenic therapy for glioblastoma: current status and future prospects.Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas.Advances in bladder cancer imaging.ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.The role of magnetic resonance imaging biomarkers in clinical trials of treatment response in cancer Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma.Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.

P2860

Q26829873-DD524B3C-2E8E-40A5-9A62-6116BD52BBB5 Q26853308-E0B283FD-A4E9-4651-840B-9C8DCEB905CA Q26853516-AD0857AB-A3AD-4AFC-A05C-00651D2F38D8 Q28066044-408B2BA5-09EA-4579-9A60-194F8DE38DB1 Q30413713-F383702C-C631-4535-BF35-3545E7442695 Q30454883-81CEB23C-F6FB-4A85-A62D-30F8C617998B Q30577397-7D211CA7-DE56-4033-A901-A7EF1081852D Q30652283-6AFCFCA9-31DA-4AB8-8268-1609C04C4018 Q30692995-39260ECF-EB1D-4E1A-8D7D-B3199C4B458F Q30737224-3AF30A45-50AB-4AC8-8628-A8ACC99ACF1E Q30764736-5E245790-F14A-4E0C-981E-7ED69B012C31 Q30870628-E8C34B27-031F-4218-AF98-36DB59F5B1AA Q30907831-28751573-A57C-4603-B6CF-AA43AEF471A1 Q30983681-6F141800-93EA-4494-94CB-05D45959A1F6 Q31113520-F346BF91-3EB5-42F8-957A-2C2D4B02B99F Q33620506-6046CB75-5A03-489C-87CA-E08D72EE40C1 Q33693500-37722DF8-98EE-4EA7-BA0E-1BE90A92D2AA Q33793253-7EBA6B04-7F30-448E-A0CF-B3E939000639 Q33810394-5D156481-2E54-4CFB-A9EF-2AC2C31B4FF4 Q33843085-AB22872E-5DA7-42D7-B5CC-07BB7A4B33B2 Q33888366-B52887A3-E662-4A84-821E-A82FDA437D71 Q33956040-80B43ACC-01D9-48F4-A7A9-131B8A4D6468 Q33959196-16AD67C3-4A85-4518-9B96-DD00D5E64743 Q34133089-9CD74E44-2514-457D-A83B-316E981F7D7E Q34145245-72025486-57D0-4AD7-9FA3-EE73AADADE8E Q34369465-483A2323-D821-44B0-BEBD-E0F70956C019 Q34480549-3854C125-43CE-44A7-B4AF-BCEFAA64A3F1 Q34515465-7A8AA9C0-D0BA-4D28-84EA-FEEF43B89AD2 Q34523319-1CF007D3-0797-4D04-B5E7-532791127154 Q34538659-96754B43-C7A6-46C8-BBB8-4CC1DCC0D4A7 Q34553361-E4A9056E-FBEB-4373-BB9B-3F6B561C1A22 Q34662750-2A764320-C1CB-45B3-943B-6631203143D1 Q34712780-A67D7282-E9D9-4A60-B2EB-F819824078A7 Q34776912-66166968-562B-4624-B089-C05F67713F1D Q34935862-1BAB2A76-9688-43D5-9138-51BA3D3D41DB Q34992526-EBC7CB66-8999-46C5-BBD0-627E753CB9FB Q35028897-3496F77E-ABB4-4CF3-8B19-E523CBA1DE19 Q35072927-7D598718-E813-41DB-AFF7-A89B4C77ED33 Q35170377-583FBA86-C9AD-40D2-BD78-0798B4EC67EB Q35225259-7CF4A42E-8C97-45B1-A405-49D7FDA94141

P2860

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

http://www.wikidata.org/entity/Q33475538

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Recurrent glioblastoma multifo ...... onse to bevacizumab treatment.

@ast

Recurrent glioblastoma multifo ...... onse to bevacizumab treatment.

@en

type

label

Recurrent glioblastoma multifo ...... onse to bevacizumab treatment.

@ast

Recurrent glioblastoma multifo ...... onse to bevacizumab treatment.

@en

prefLabel

Recurrent glioblastoma multifo ...... onse to bevacizumab treatment.

@ast

Recurrent glioblastoma multifo ...... onse to bevacizumab treatment.

@en

P1433

Q33475538-B8140404-958B-4FA7-AE56-C83E9C9EF763

P1476

Q33475538-EF1E4207-0A89-49A8-B03E-54AF7AA3A255

P2093

Q33475538-0701BF5D-2D8B-4CF6-91F9-E26A72C7136A

Q33475538-1AB5476B-22DD-4B74-B054-732BF34FE027

Q33475538-3293E192-5282-4E0E-8F97-049AFDEA41DE

Q33475538-5E16B387-14AA-4058-A67D-4CBE726FFD21

Q33475538-60196AE9-CE21-47B2-8CDA-678B404C6A8F

Q33475538-81384B65-402E-4F94-92EE-8D06AD76E8B0

Q33475538-83165E1D-9ABD-4F12-A0B5-11F0BCC8FBAC

Q33475538-A0BB2842-BFCE-4AD3-A2B3-7CAEF6D04CA5

Q33475538-C17D53EE-BDE4-4D0C-A4F6-BA9157D28257

Q33475538-C8A68017-F0AB-46F0-8587-3BED672F746F

P304

Q33475538-A4E5D3DC-2034-42F7-A253-299BB8866399

P31

Q33475538-3A646B69-FD6C-4866-8B6F-8CD4539D0D64

P356

Q33475538-A57FF733-07EA-49D0-9E58-27891C478C1D

P407

Q33475538-73468258-9B72-4100-B194-6EBD6866BE4C

P433

Q33475538-51E6F46C-0428-4BC1-B545-95439BEFFA44

P478

Q33475538-D4938E6D-F25A-4FB2-8FE5-F9F05573C8D2

P50

Q33475538-1860334F-1E61-4D89-821A-29BEB5016A41

Q33475538-780AD038-FAB0-40EF-8B40-A94180B3F919

Q33475538-8D02646D-DA20-4D5A-A778-41D94C8749E5

P577

Q33475538-E68AE8FD-97DD-4503-B890-1694EF988D54

P5875

Q33475538-018C1BE2-2B90-488E-A39B-C28FFACF0AE1

P698

Q33475538-2FC7A13B-601F-4472-A7C5-F731A34D4669

P921

Q33475538-44D3BFE1-FFCB-49C2-9AE5-E778083718D2

Q33475538-E8564E5E-89A9-4E72-A029-EB52CA904419

P356

RADIOL.2521081534

P1433

P1476

Recurrent glioblastoma multifo ...... onse to bevacizumab treatment.

@en

P2093

Albert Lai

http://www.w3.org/2001/XMLSchema#string

David Gjertson

http://www.w3.org/2001/XMLSchema#string

Hyun J Kim

http://www.w3.org/2001/XMLSchema#string

Jeffry Alger

http://www.w3.org/2001/XMLSchema#string

Jing Huo

http://www.w3.org/2001/XMLSchema#string

Leena Tekchandani

http://www.w3.org/2001/XMLSchema#string

Matthew S Brown

http://www.w3.org/2001/XMLSchema#string

Paul S Mischel

http://www.w3.org/2001/XMLSchema#string

Syed Rahmanuddin

http://www.w3.org/2001/XMLSchema#string

Timothy Cloughesy

http://www.w3.org/2001/XMLSchema#string

P304

182-189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1148/RADIOL.2521081534

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

252

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan Goldin

Jonathan R Young

Phioanh Nghiemphu

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26325379

http://www.w3.org/2001/XMLSchema#string

P698

19561256

http://www.w3.org/2001/XMLSchema#string

P921